Gennova's Vaccine Gets Nod From DCGI To Start Phase II And Phase III Trials

[email protected]01 Oct, 2021News

In a significant development towards India?s vaccination efforts, the Drug Controller General of India, has approved Phase II and Phase III study protocols for HGCO19, India?s first mRNA-based COVID-19 vaccine, developed by Gennova Biopharmaceuticals (Gennova). Gennova, the subsidiary of Pune based Emcure Pharmaceuticals Limited had submitted the interim clinical data of the Phase I study to the Central Drugs Standard Control Organisation (CDSCO), the Government of India's National Regulatory Authority (NRA).